Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Breast Cancer

Autologous hematopoietic stem cell transplantation for breast cancer in Europe: critical evaluation of data from the European Group for Blood and Marrow Transplantation (EBMT) Registry 1990–1999

Bone Marrow Transplantation volume 32, pages 489–494 (2003)Cite this article

Summary:

The aim of this study was to identify trends in high-dose chemotherapy (HDC) with autologous hematopoietic stem cell transplantation (ASCT) and to assess survival in a large cohort of breast cancer (BC) patients receiving this therapy in Europe from 1990 to 1999. A total of 7471 patients who received HDC with ASCT between January 1, 1990 and December 31, 1999 were reported to the European Group for Blood and Marrow Transplantation Registry. Data required for demographics and survival analysis were available for 2679 patients with high-risk primary BC; 921 patients with inflammatory BC (IBC), and 2295 patients with metastatic disease. The main evaluation parameters were progression-free survival (PFS) and overall survival (OS). Between 1990 and 1998, autotransplants for BC increased 30-fold. Significant trends included use of blood-derived rather than marrow-derived stem cells, increment of reporting centers and decrease of mortality within 100 days from transplantation. The 5-year PFS and OS probabilities were 53 and 68% for high-risk disease and 42 and 53% for IBC, respectively. For metastatic disease 5-year PFS and OS probabilities in the whole cohort were 18 and 27%, respectively, while for women transplanted in complete remission the 5-year PFS was 29%. In conclusion, HDC with ASCT has been increasingly used until 1998 and the 100-day mortality rate has been constantly less than 2% from 1995 to date. The 5-year survival of high-risk BC is related to the number of axillary nodes involved at surgery. Outcome of patients with IBC is encouraging, suggesting the need for randomized trials. Patients with metastatic disease responding to pretransplant chemotherapy and harboring ER+ tumors have a better outcome.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Winer EC, Morrow M, Osborne CK, Harris JR . Malignant tumors of the breast. In: DeVita Jr VT, Hellman S, Rosenberg SA (eds). Cancer: Principles and Practice of Oncology. Lippincott-Raven: Philadelphia, PA, 2001, pp. 1651–1716.

    Google Scholar 

  2. Greenberg PA, Hortobagyi GN, Smith TL et al. Long-term follow-up of patients with CR following combination chemotherapy for metastatic breast cancer. J Clin Oncol 1996; 14: 2197–2205.

    Article  CAS  Google Scholar 

  3. Skipper HE . Dose intensity versus total dose of chemotherapy: an experimental basis. In: De Vita VT, Hellman S, Rosenberg SA (eds). Important Advances in Oncology. Lippincott-Raven: Philadelphia, PA, 1990, pp. 43–64.

    Google Scholar 

  4. Lazarus HM . Hematopoietic progenitor cell transplantation in breast cancer: current status and future directions. Cancer Invest 1998; 16: 102–126.

    Article  CAS  Google Scholar 

  5. Crown J . High-dose chemotherapy of metastatic breast cancer: the end of the beginning? Br J Cancer 1997; 75: 467–479.

    Article  CAS  Google Scholar 

  6. Gianni AM, Siena S, Bregni M et al. Granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation. Lancet 1989; 2: 580–585.

    Article  CAS  Google Scholar 

  7. Siena S, Bregni M, Brando B et al. Circulation of CD34+ hematopoietic stem cells in the peripheral blood of high-dose cyclophosphamide-treated patients: enhancement by intravenous recombinant human granulocyte–macrophage colony-stimulating factor. Blood 1989; 74: 1905–1914.

    CAS  Google Scholar 

  8. Schmitz N, Linch DC, Dreger P et al. Randomized trial of filgrastim-mobilized peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 1996; 347: 353–357.

    Article  CAS  Google Scholar 

  9. Siena S, Schiavo R, Pedrazzoli P, Carlo-Stella C . Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy. J Clin Oncol 2000; 18: 1360–1377.

    Article  CAS  Google Scholar 

  10. Neymark N, Rosti G : Patient management strategies and transplantation techniques in European stem cell transplantation centers offering breast cancer patients high-dose chemotherapy with peripheral blood stem cell support: a joint report from the EORTC and EBMT. Haematologica 2000; 85: 733–744.

    CAS  Google Scholar 

  11. Stadtmauer EA, O'Neill A, Goldstein LJ et al. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. N Engl J Med 2000; 342: 1069–1076.

    Article  CAS  Google Scholar 

  12. Crump M, Gluck S, Stewart D et al. A randomized trial of high-dose chemotherapy (HDC) with autologous peripheral blood stem cell support (ASCT) compared to standard therapy in women with metastatic breast cancer: a National Cancer Institute of Canada (NCIC) Clinical Trials Group Study. J Clin Oncol 2001; 20: 21a (Abstr).

    Google Scholar 

  13. Bergh J, Wiklund T, Erikstein B et al. Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study. Lancet 2000; 356: 1384–1391.

    Article  CAS  Google Scholar 

  14. Peters W, Rosner G, Vrendeburgh J et al. Updated results of a prospective, randomized comparison of two doses of combination alkylating agents as consolidation after CAF in high-risk primary breast cancer involving ten or more axillary lymph nodes: CALBG 9082/SWOG 9114/NCIC Ma. 13. J Clin Oncol 2001; 20: 21a (Abstr).

    Google Scholar 

  15. Gianni A, Bonadonna G . Five-year results of the randomized clinical trial comparing standard versus high-dose myeloablative chemotherapy in the adjuvant treatment of breast cancer with >3 positive nodes. J Clin Oncol 2001; 20: 21a (Abstr).

    Google Scholar 

  16. Gianni L : High-dose chemotherapy for breast cancer: any use for it. Ann Oncol 2002; 13: 650–652.

    Article  CAS  Google Scholar 

  17. Pedrazzoli P, Siena S . Clinical results in 2001 show high dose therapy and hematopoietic progenitor cell transplantation as a therapeutic option for breast cancer. Haematologica 2001; 86: 900–907.

    CAS  PubMed  Google Scholar 

  18. Berry DA, Broadwater G, Klein JP et al. High-dose versus standard chemotherapy in metastatic breast cancer: comparison of cancer and leukemia group B trials with data from the autologous blood and marrow transplant registry. J Clin Oncol 2002; 20: 743–750.

    Article  CAS  Google Scholar 

  19. Gratwohl A, Hermans J . Bone marrow transplantation activity in Europe 1992: report from the European Group for Bone Marrow Transplantation (EBMT). Bone Marrow Transplant 1994; 13: 5–10.

    CAS  Google Scholar 

  20. Gratwohl A, Passweg J, Baldomero H, Urbano-Hispizua A . European Group for Blood and Marrow Transplantation (EBMT), hematopoietic stem cell transplantation activity in Europe 1999. Bone Marrow Transplant 2001; 27: 899–916.

    Article  CAS  Google Scholar 

  21. Kaplan EL, Meier P . Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481.

    Article  Google Scholar 

  22. Cox DR . Regression models and life tablets. J R Stat Soc B 1972; 3: 187–202.

    Google Scholar 

  23. Antman KH, Rowlings PA, Vaughn WP et al. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J Clin Oncol 1997; 15: 1870–1879.

    Article  CAS  Google Scholar 

  24. Siena S, Bregni M, Di Nicola M et al. Durability of hematopoiesis following autografting with peripheral blood hematopoietic progenitors. Ann Oncol 1994; 5: 935–941.

    Article  CAS  Google Scholar 

  25. Stadtmauer EA, O'Neill A, Goldstein LJ et al. Conventional-dose chemotherapy with high-dose chemotherapy plus autologous stem cell transplantation for metastatic breast cancer: 5-year update of the Philadelphia trial. J Clin Oncol 2002; 21: 43a (Abstr).

    Google Scholar 

  26. Rodenhuis S, Bontenbal M, Beex L et al. Randomized phase III study of high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin in operable breast cancer with 4 or more axillary lymph nodes. J Clin Oncol 2000; 19: 74a (Abstr).

    Google Scholar 

  27. Crown JP, Lind M, Gould A et al. High dose chemotherapy with autograft (PBP) support is not superior cyclophosphamide, methotrexare and FU following doxorubicin induction in patients with breast cancer and 4 or more involved axillary lymph nodes: the anglo-celtic I study. J Clin Oncol 2002; 21: 42a (Abstr).

    Google Scholar 

  28. Zander AR, Kruger W, Kroger N et al. High-dose chemotherapy with autologous hematopoietic stem-cell support (HSCS) vs. standard dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: first result of a randomized trial. J Clin Oncol 2002; 21: 415a (Abstr).

    Google Scholar 

  29. Jaiyesimi IA, Buzdar AU, Hortobagyi G . Inflammatory breast cancer: a review. J Clin Oncol 1992; 10: 1014–1024.

    Article  CAS  Google Scholar 

  30. Thomas F, Arriagada R, Spielmann M et al. Pattern of failure in patients with inflammatory breast cancer treated by alternating radiotherapy and chemotherapy. Cancer 1995; 76: 2286–2290.

    Article  CAS  Google Scholar 

  31. Viens P, Penault-Llorca F, Jacquemier J et al. High-dose chemotherapy and haematopoietic stem cell transplantation for inflammatory breast cancer: pathologic response and outcome. Bone Marrow Transplant 1998; 21: 249–254.

    Article  CAS  Google Scholar 

  32. Rowlings PA, Williams SF, Antman KH et al. Factors correlated with progression-free survival after high-dose chemotherapy and hematopoietic stem cell transplantation for metastatic breast cancer. JAMA 1999; 282: 1335–1343.

    Article  CAS  Google Scholar 

  33. Hortobagyi GN . Can we cure limited metastatic breast cancer? J Clin Oncol 2002; 20: 620–623.

    Article  Google Scholar 

  34. Lotz JP, Cure H, Janvier M et al. High dose chemotherapy with hematopoietic stem cell transplantation for metastatic breast cancer: results of the French protocol PEGASE 04. J Clin Oncol 1999; 18: 43a (Abstr).

    Google Scholar 

Download references

Acknowledgements

We are grateful to the EBMT London office and to all investigators in EBMT centers who made this study possible by providing clinical data to the EBMT Solid Tumor Registry.

Author information

Authors and Affiliations

  1. S.C. Divisione di Oncologia Medica Falck, Ospedale Niguarda Ca' Granda, Milano, Italy

    P Pedrazzoli, R Schiavo, O Carminati & S Siena

  2. Unità Operativa di Oncologia Medica, Ospedale Civile, Ravenna, Italy

    P Ferrante, U De Giorgi, M Marangolo & G Rosti

  3. Ibn-i Sina Hospital, Sihhiye, Ankara, Turkey

    A Kulekci & T Demirer

Authors
  1. P Pedrazzoli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P Ferrante
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A Kulekci
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R Schiavo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. U De Giorgi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. O Carminati
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M Marangolo
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. T Demirer
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. S Siena
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. G Rosti
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

on behalf of the European Group for Blood and Marrow Transplantation (EBMT), Solid Tumors Working Party

Corresponding author

Correspondence to P Pedrazzoli.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pedrazzoli, P., Ferrante, P., Kulekci, A. et al. Autologous hematopoietic stem cell transplantation for breast cancer in Europe: critical evaluation of data from the European Group for Blood and Marrow Transplantation (EBMT) Registry 1990–1999. Bone Marrow Transplant 32, 489–494 (2003). https://doi.org/10.1038/sj.bmt.1704153

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1704153

Keywords

This article is cited by

Search

Advanced search

Quick links